1. Home
  2. CMPS vs MPLT Comparison

CMPS vs MPLT Comparison

Compare CMPS & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo COMPASS Pathways Plc American Depository Shares

CMPS

COMPASS Pathways Plc American Depository Shares

HOLD

Current Price

$6.14

Market Cap

778.7M

Sector

Health Care

ML Signal

HOLD

MPLT

MapLight Therapeutics Inc.

N/A

Current Price

$18.10

Market Cap

811.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CMPS
MPLT
Founded
2020
2018
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
778.7M
811.3M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
CMPS
MPLT
Price
$6.14
$18.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
4
Target Price
$27.14
$31.00
AVG Volume (30 Days)
4.4M
123.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
0.86
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.25
$12.24
52 Week High
$8.90
$21.55

Technical Indicators

Market Signals
Indicator
CMPS
MPLT
Relative Strength Index (RSI) 40.28 48.19
Support Level $5.95 $16.17
Resistance Level $7.02 $20.20
Average True Range (ATR) 0.46 1.32
MACD -0.12 0.03
Stochastic Oscillator 3.82 29.47

Price Performance

Historical Comparison
CMPS
MPLT

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.

Share on Social Networks: